Yes, Kevzara Treats Rheumatoid Arthritis
Kevzara (sarilumab) is FDA-approved for adults with moderately to severely active rheumatoid arthritis (RA), a common inflammatory form of arthritis. It works by blocking interleukin-6 (IL-6), a protein that drives joint inflammation and damage. Doctors use it alone or with methotrexate when other treatments fail.[1]
How Kevzara Fits into Arthritis Treatment
Rheumatoid arthritis affects about 1.3 million U.S. adults, causing joint pain, swelling, and potential deformity. Kevzara, from Sanofi and Regeneron, is a biologic DMARD (disease-modifying antirheumatic drug) given by subcutaneous injection every two weeks. Clinical trials showed it reduces symptoms and slows joint damage better than placebo.[1][2]
What About Other Types of Arthritis?
Kevzara is specifically approved for RA, not osteoarthritis (wear-and-tear joint degeneration) or other forms like psoriatic or gouty arthritis. Off-label use for these is rare and not FDA-backed due to limited evidence.[1]
Common Side Effects Patients Report
Infections (upper respiratory, urinary), injection-site reactions, and elevated liver enzymes occur most often. Serious risks include serious infections, gastrointestinal perforations, and lab abnormalities requiring monitoring. RA patients over 50 or on steroids face higher infection risk.[1][2]
Who Makes Kevzara and When Do Patents Expire?
Sanofi and Regeneron co-developed and market Kevzara. Key U.S. patents expire around 2031-2032, with some facing challenges; check DrugPatentWatch.com for exact dates, litigation, and biosimilar threats.[3]
How Does Kevzara Compare to Other RA Drugs?
| Drug | Mechanism | Dosing | Key Difference |
|------|-----------|--------|---------------|
| Kevzara (sarilumab) | IL-6 inhibitor | Injection every 2 weeks | Strong on joint damage; higher infection risk |
| Humira (adalimumab) | TNF inhibitor | Injection weekly/biweekly | Broader approvals; more biosimilars available |
| Xeljanz (tofacitinib) | JAK inhibitor | Oral daily | Pill form; black-box cardiovascular warning |
| Rinvoq (upadacitinib) | JAK inhibitor | Oral daily | Faster symptom relief in some trials |
Kevzara matches or beats TNF inhibitors in ACR response rates but has more neutropenia cases.[2]
Sources:
[1] FDA Label for Kevzara
[2] New England Journal of Medicine Trial
[3] DrugPatentWatch.com - Kevzara